165 related articles for article (PubMed ID: 17764755)
1. Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency.
Kostelidou K; Trakas N; Tzartos SJ
J Neuroimmunol; 2007 Oct; 190(1-2):44-52. PubMed ID: 17764755
[TBL] [Abstract][Full Text] [Related]
2. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera.
Tzartos SJ; Bitzopoulou K; Gavra I; Kordas G; Jacobson L; Kostelidou K; Lagoumintzis G; Lazos O; Poulas K; Sideris S; Sotiriadis A; Trakas N; Zisimopoulou P
Ann N Y Acad Sci; 2008; 1132():291-9. PubMed ID: 18567880
[TBL] [Abstract][Full Text] [Related]
3. Specific immunoadsorption of the autoantibodies from myasthenic patients using the extracellular domain of the human muscle acetylcholine receptor alpha-subunit. Development of an antigen-specific therapeutic strategy.
Psaridi-Linardaki L; Trakas N; Mamalaki A; Tzartos SJ
J Neuroimmunol; 2005 Feb; 159(1-2):183-91. PubMed ID: 15652418
[TBL] [Abstract][Full Text] [Related]
4. Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains.
Zisimopoulou P; Lagoumintzis G; Poulas K; Tzartos SJ
J Neuroimmunol; 2008 Aug; 200(1-2):133-41. PubMed ID: 18603305
[TBL] [Abstract][Full Text] [Related]
5. Expression and characterization of soluble forms of the extracellular domains of the beta, gamma and epsilon subunits of the human muscle acetylcholine receptor.
Kostelidou K; Trakas N; Zouridakis M; Bitzopoulou K; Sotiriadis A; Gavra I; Tzartos SJ
FEBS J; 2006 Aug; 273(15):3557-68. PubMed ID: 16884496
[TBL] [Abstract][Full Text] [Related]
6. Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis.
Lagoumintzis G; Zisimopoulou P; Kordas G; Lazaridis K; Poulas K; Tzartos SJ
Autoimmunity; 2010 Aug; 43(5-6):436-45. PubMed ID: 20187712
[TBL] [Abstract][Full Text] [Related]
7. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.
Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ
J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243
[TBL] [Abstract][Full Text] [Related]
8. Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains.
Lazaridis K; Evaggelakou P; Bentenidi E; Sideri A; Grapsa E; Tzartos SJ
J Neuroimmunol; 2015 Jan; 278():19-25. PubMed ID: 25595248
[TBL] [Abstract][Full Text] [Related]
9. Isolation and functional characterization of anti-acetylcholine receptor subunit-specific autoantibodies from myasthenic patients: receptor loss in cell culture.
Sideris S; Lagoumintzis G; Kordas G; Kostelidou K; Sotiriadis A; Poulas K; Tzartos SJ
J Neuroimmunol; 2007 Sep; 189(1-2):111-7. PubMed ID: 17617475
[TBL] [Abstract][Full Text] [Related]
10. Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy.
Skriapa L; Zisimopoulou P; Trakas N; Grapsa E; Tzartos SJ
J Neuroimmunol; 2014 Nov; 276(1-2):150-8. PubMed ID: 25262156
[TBL] [Abstract][Full Text] [Related]
11. Myasthenic sera recognize the human acetylcholine receptor bound to thymopoietin.
Morel E; Vernet-der Garabedian B; Raimond F; Audhya TK; Goldstein G; Bach JF
Eur J Immunol; 1987 Aug; 17(8):1109-13. PubMed ID: 3622601
[TBL] [Abstract][Full Text] [Related]
12. Antigen-specific apheresis of autoantibodies in myasthenia gravis.
Lazaridis K; Zisimopoulou P; Lagoumintzis G; Skriapa L; Trakas N; Evangelakou P; Kanelopoulos I; Grapsa E; Poulas K; Tzartos S
Ann N Y Acad Sci; 2012 Dec; 1275():7-12. PubMed ID: 23278571
[TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the epsilon-subunit of the acetylcholine receptor.
Ragheb S; Mohamed M; Lisak RP
J Neuroimmunol; 2005 Feb; 159(1-2):137-45. PubMed ID: 15652413
[TBL] [Abstract][Full Text] [Related]
14. Expression of human AChR extracellular domain mutants with improved characteristics.
Lazaridis K; Zisimopoulou P; Giastas P; Bitzopoulou K; Evangelakou P; Sideri A; Tzartos SJ
Int J Biol Macromol; 2014 Feb; 63():210-7. PubMed ID: 24246999
[TBL] [Abstract][Full Text] [Related]
15. Future therapeutic strategies in autoimmune myasthenia gravis.
Psaridi-Linardaki L; Mamalaki A; Tzartos SJ
Ann N Y Acad Sci; 2003 Sep; 998():539-48. PubMed ID: 14592926
[TBL] [Abstract][Full Text] [Related]
16. Myasthenia gravis studied by monoclonal antibodies to the acetylcholine receptor.
Tzartos SJ
In Vivo; 1988; 2(1):105-10. PubMed ID: 2979808
[TBL] [Abstract][Full Text] [Related]
17. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
18. Neuronal acetylcholine receptor alpha9-subunit: a possible central nervous system autoantigen.
Tüzün E
Med Hypotheses; 2006; 67(3):561-5. PubMed ID: 16725279
[TBL] [Abstract][Full Text] [Related]
19. Scale up and safety parameters of antigen specific immunoadsorption of human anti-acetylcholine receptor antibodies.
Lagoumintzis G; Zisimopoulou P; Trakas N; Grapsa E; Poulas K; Tzartos SJ
J Neuroimmunol; 2014 Feb; 267(1-2):1-6. PubMed ID: 24412396
[TBL] [Abstract][Full Text] [Related]
20. Electron microscopic evidence for the assembly of soluble pentameric extracellular domains of the nicotinic acetylcholine receptor.
Tierney ML; Unwin N
J Mol Biol; 2000 Oct; 303(2):185-96. PubMed ID: 11023785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
